Lori Anne Kunkel's most recent trade in Enliven Therapeutics Inc was a trade of 17,126 Stock Option (right to buy) done . Disclosure was reported to the exchange on Feb. 12, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Enliven Therapeutics Inc | Lori Anne Kunkel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 17,126 | 17,126 | - | - | Stock Option (right to buy) | |
| ORIC Pharma Inc | Lori Anne Kunkel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Lori Anne Kunkel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2025 | 15,958 | 3,741 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Lori Anne Kunkel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 17 Dec 2025 | 15,958 | 30,712 | - | 1.1 | 17,873 | Common Stock |
| ORIC Pharma Inc | Lori Anne Kunkel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2025 | 10,000 | 15,600 | - | - | Stock Option (right to buy) | |
| ORIC Pharma Inc | Lori Anne Kunkel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.90 per share. | 08 Dec 2025 | 10,000 | 84,200 | - | 7.9 | 79,000 | Common Stock |
| ORIC Pharma Inc | Lori Anne Kunkel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2025 | 5,534 | 0 | - | - | Stock Option (right to buy) | |
| ORIC Pharma Inc | Lori Anne Kunkel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.75 per share. | 04 Dec 2025 | 5,534 | 74,200 | - | 3.8 | 20,753 | Common Stock |
| Nurix Therapeutics Inc | Lori Anne Kunkel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2025 | 25,000 | 25,000 | - | - | Director Stock Option (right to buy) | |
| ORIC Pharma Inc | Lori Anne Kunkel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.75 per share. | 03 Mar 2025 | 27,666 | 48,166 | - | 3.8 | 103,748 | Common Stock |
| ORIC Pharma Inc | Lori Anne Kunkel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 27,666 | 5,534 | - | - | Stock Option (right to buy) | |
| ORIC Pharma Inc | Lori Anne Kunkel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 20,500 | 0 | - | - | Stock Option (right to buy) | |
| ORIC Pharma Inc | Lori Anne Kunkel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.33 per share. | 03 Mar 2025 | 20,500 | 68,666 | - | 6.3 | 129,765 | Common Stock |
| Enliven Therapeutics Inc | Lori Anne Kunkel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 15,368 | 15,368 | - | - | Stock Option (right to buy) | |
| ORIC Pharma Inc | Lori Anne Kunkel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Lori Anne Kunkel | Director | 17 Jul 2024 | 54,027 | 0 | - | 0 | Common Stock | ||
| ORIC Pharma Inc | Lori Anne Kunkel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 25,600 | 25,600 | - | - | Stock Option (right to buy) | |
| ORIC Pharma Inc | Lori Anne Kunkel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2024 | 20,500 | 33,200 | - | - | Stock Option (right to buy) | |
| ORIC Pharma Inc | Lori Anne Kunkel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.75 per share. | 03 Jun 2024 | 20,500 | 20,500 | - | 3.8 | 76,875 | Common Stock |
| Nurix Therapeutics Inc | Lori Anne Kunkel | Director | 20 May 2024 | 25,000 | 25,000 | - | - | Director Stock Option (right to buy) | ||
| Enliven Therapeutics Inc | Lori Anne Kunkel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2024 | 37,882 | 37,882 | - | - | Stock Option (right to buy) | |
| ORIC Pharma Inc | Lori Anne Kunkel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 20,500 | 20,500 | - | - | Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Lori Anne Kunkel | Director | 04 May 2023 | 25,000 | 25,000 | - | - | Director Stock Option (right to buy) | ||
| Nurix Therapeutics Inc | Lori Anne Kunkel | Director | 05 May 2022 | 17,500 | 17,500 | - | - | Director Stock Option (right to buy) | ||
| Curis Inc | Lori Anne Kunkel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 85,000 | 85,000 | - | - | Non Qualified Stock Option | |
| ORIC Pharma Inc | Lori Anne Kunkel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 16,625 | 16,625 | - | - | Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Lori Anne Kunkel | Director | 06 May 2021 | 17,500 | 17,500 | - | - | Director Stock Option (right to buy) |